|
Fibrinogen/fibrin
Citations 1-10 of 49 total displayed.
|
Most recent content
(27 Nov 2007):
|
- Editorials
Ablation for Atrial Fibrillation: Can We Decrease Thromboembolism Without Increasing the Risk for Bleeding?
- Samuel J. Asirvatham
Circulation 2007; 116: 2517-2519, doi:10.1161/CIRCULATIONAHA.107.741454
[Full text]
|
Past content
(since May 2001):
|
- Epidemiology
Exposure to Secondhand Smoke and Biomarkers of Cardiovascular Disease Risk in Never-Smoking Adults
- Andrea Venn and John Britton
Circulation 115: 990 -995; published online before print as doi:10.1161/CIRCULATIONAHA.106.648469
[Abstract]
[Full text]
- Epidemiology
Diurnal, Seasonal, and Blood-Processing Patterns in Levels of Circulating Fibrinogen, Fibrin D-Dimer, C-Reactive Protein, Tissue Plasminogen Activator, and von Willebrand Factor in a 45-Year-Old Population
- Alicja R. Rudnicka, Ann Rumley, Gordon D.O. Lowe, and David P. Strachan
Circulation 115: 996 -1003; published online before print as doi:10.1161/CIRCULATIONAHA.106.635169
[Abstract]
[Full text]
- Articles
Exposure to Secondhand Smoke and Biomarkers of Cardiovascular Disease Risk in Never-Smoking Adults
- Andrea Venn and John Britton
Circulation published February 12, 2007, doi:10.1161/CIRCULATIONAHA.106.648469
[Abstract]
- Articles
Diurnal, Seasonal, and Blood-Processing Patterns in Levels of Circulating Fibrinogen, Fibrin D-Dimer, C-Reactive Protein, Tissue Plasminogen Activator, and von Willebrand Factor in a 45-Year-Old Population
- Alicja R. Rudnicka, Ann Rumley, Gordon D.O. Lowe, and David P. Strachan
Circulation published February 12, 2007, doi:10.1161/CIRCULATIONAHA.106.635169
[Abstract]
- Vascular Medicine
First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer Technology: A Phase 1a Pharmacodynamic Evaluation of a Drug-Antidote Pair for the Controlled Regulation of Factor IXa Activity
- Christopher K. Dyke, Steven R. Steinhubl, Neal S. Kleiman, Richard O. Cannon, Laura G. Aberle, Min Lin, Shelley K. Myles, Chiara Melloni, Robert A. Harrington, John H. Alexander, Richard C. Becker, and Christopher P. Rusconi
Circulation 114: 2490 -2497; published online before print as doi:10.1161/CIRCULATIONAHA.106.668434
[Abstract]
[Full text]
- Articles
First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer Technology. A Phase 1a Pharmacodynamic Evaluation of a Drug-Antidote Pair for the Controlled Regulation of Factor IXa Activity
- Christopher K. Dyke, Steven R. Steinhubl, Neal S. Kleiman, Richard O. Cannon, Laura G. Aberle, Min Lin, Shelley K. Myles, Chiara Melloni, Robert A. Harrington, John H. Alexander, Richard C. Becker, and Christopher P. Rusconi
Circulation published November 13, 2006, doi:10.1161/CIRCULATIONAHA.106.668434
[Abstract]
- Epidemiology
Additive Value of Immunoassay-Measured Fibrinogen and High-Sensitivity C-Reactive Protein Levels for Predicting Incident Cardiovascular Events
- Samia Mora, Nader Rifai, Julie E. Buring, and Paul M Ridker
Circulation 114: 381 -387; published online before print as doi:10.1161/CIRCULATIONAHA.106.634089
[Abstract]
[Full text]
- Articles
Additive Value of Immunoassay-Measured Fibrinogen and High-Sensitivity C-Reactive Protein Levels for Predicting Incident Cardiovascular Events
- Samia Mora, Nader Rifai, Julie E. Buring, and Paul M Ridker
Circulation published July 24, 2006, doi:10.1161/CIRCULATIONAHA.106.634089
[Abstract]
- Images in Cardiovascular Medicine
Architecture of Intracoronary Thrombi in ST-Elevation Acute Myocardial Infarction: Time Makes the Difference
- Farzin Beygui, Jean-Philippe Collet, Chandrasekaran Nagaswami, John W. Weisel, and Gilles Montalescot
Circulation 2006; 113: e21-23e, doi:10.1161/CIRCULATIONAHA.105.551705
[Full text]
|
|
